Skip to main content
Fig. 5 | BMC Pharmacology and Toxicology

Fig. 5

From: Post-marketing safety of elacestrant in breast cancer: a pharmacovigilance investigation using the FDA adverse event reporting system

Fig. 5

Scanning for elacestrant-related AEs based on the FAERS database. A The bubble chart shows the ROR of the top 10 PT AEs, with the colors indicating the number of reported cases and the bubble size representing the magnitude of the ROR values. B The pie chart illustrates the proportion of drug-related AEs at different SOC levels. C Sankey diagram depicting the hierarchical relationship of PTs for 10 categories of elacestrant-related AEs in MedDRA. NES indicates not classified elsewhere; PT, preferred term; HLT, high-level term; HLGT, high-level group term; and SOC, system organ class

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us